Testing the Combination of APG-1252 and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
Status:
Not yet recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
This phase I trial tests the safety, side effects, and best dose of combination pelcitoclax
(APG-1252) and cobimetinib in treating patients with ovarian and endometrial cancers that
have come back (recurrent). APG-1252 is a drug that inhibits activity of proteins that
prevent cell death, leading to increased cell death and reduced cell growth. Cobimetinib is
used in patients whose cancer has a mutated (changed) form of a gene called BRAF. It is in a
class of medications called kinase inhibitors. It works by blocking the action of an abnormal
protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer
cells. Giving APG-1252 in combination with cobimetinib may help slow the growth or stop the
spread of cancer cells in patients with recurrent ovarian and endometrial cancers.